Here are the DEF 14A proxy statements from Moderna, Inc. (MRNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MRNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRNA filings page.
Moderna is asking shareholders to vote at its virtual 2026 annual meeting on five items, including electing two Class II directors, approving executive pay on an advisory basis, setting say‑on‑pay frequency to one year, and ratifying Ernst & Young as auditor for 2026.
The proxy highlights 2025 results: $1.9 billion in total revenue, about $2.2 billion in annual cost savings (a 30% reduction from 2024), and $8.1 billion in cash, cash equivalents and investments as of December 31, 2025. The company reports three regulatory approvals in infectious disease vaccines and eight Phase 2/3 oncology trials for intismeran autogene with Merck.
mNEXSPIKE became a key U.S. product, representing roughly 24% of all U.S. retail COVID vaccinations in 2025 and nearly one‑third among adults 65+. The Board approved a $1.5 billion five‑year term loan facility to add non‑dilutive capital and oversaw cost discipline, digital investments and expansion of global manufacturing sites.
The nine‑member, staggered Board includes eight independent directors, three women and multiple members with scientific and healthcare backgrounds. Executive pay is positioned as strongly performance‑linked, with 2025 corporate bonuses funded at 170% of target and at‑risk compensation at 91% of target pay for the CEO and 89% for other named executives.